Your Messages Inbox
Your Article Summary
See Latest ArticlesRegulatory update for REZONIC (casopitant mesylate)
GlaxoSmithKline, 06/24/09
GlaxoSmithKline confirmed that it has received a complete response letterfrom the FDA related to the application for casopitant. The company is reviewing this letter and will engage with the FDA to determine appropriate next steps. one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Tricare contracts may be re-bid after losing plans protest
American Medical News , 11/25/09
GSK Regulatory Update: Avodart
GlaxoSmithKline, 11/24/09
Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09
Article Search
Sponsor